(Q35043113)

6 August 2017

1 reference

title

Principles of tumor immunosurveillance and implications for immunotherapy (English)

1 reference

6 August 2017

1 reference

Adrian F Ochsenbein

1

1 reference

6 August 2017

publication date

1 December 2002

1 reference

6 August 2017

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

12

1 reference

6 August 2017

page(s)

1043-1055

1 reference

Neutralizing antiviral B cell responses

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Tumor immunology: the first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Cancer; a biological approach. I. The processes of control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Immunological aspects of malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

A fresh look at tumor immunosurveillance and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Regulation of the proinflammatory effects of Fas ligand (CD95L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Assessment of risk of cancer after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Decreased tumor surveillance in perforin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Fc receptors are required in passive and active immunity to melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

B cells inhibit induction of T cell-dependent tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

T-cell memory: the connection between function, phenotype and migration pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Chance encounters and organized rendezvous.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Fibroblasts as efficient antigen-presenting cells in lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11(-)/-) mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Regulation of the immune response by antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Immunological ignorance of silent antigens as an explanation of tumor evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

The origin and mechanism of the allograft reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Immune surveillance against a solid tumor fails because of immunological ignorance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

A Theory of Self-Nonself Discrimination: Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Tolerance, danger, and the extended family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Co-stimulation in T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

CD27: marker and mediator of T-cell activation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

T cell co-stimulatory molecules other than CD28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding, and costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Can Co‐stimulated Tumor Immunity be Therapeutically Efficacious?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Differential T cell costimulatory requirements in CD28-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Cross-presentation: a general mechanism for CTL immunity and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Cross-presentation in viral immunity and self-tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

The induction of tolerance by dendritic cells that have captured apoptotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Cross-presentation, dendritic cells, tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

The effect of allogeneic presensitization on H-Y graft survival and in vitro cell-mediated responses to H-y antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Induction of H-2-restricted cytotoxic T cells: in vivo induction has the appearance of being unrestricted

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

CD4 T cells and their role in antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Constitutive class I-restricted exogenous presentation of self antigens in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Spinning molecular immunology into successful immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Principles for adoptive T cell therapy of human viral diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Dendritic cells: On the move from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Intralymphatic immunization enhances DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

The prime-boost strategy: exciting prospects for improved vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Signaling through OX40 (CD134) breaks peripheral T-cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Electroporation and commercial liposomes efficiently deliver soluble protein into the MHC class I presentation pathway. Priming in vitro and in vivo for class I-restricted recognition of soluble antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Stress proteins and immunity mediated by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

21 January 2018

Vaccines and vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

21 January 2018

On immunological memory

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Monoclonal antibody therapies-a 'constant' threat to cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Class I-restricted presentation of exogenous antigen acquired by Fcγ receptor-mediated endocytosis is regulated in dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Experimental studies on the pathogenesis of contact eczema in the guinea-pig.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

A new analysis of allogeneic interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

A cell culture model for T lymphocyte clonal anergy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Costimulatory approaches to adoptive immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Prevention of graft versus host disease by inactivation of host antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

1 reference

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Engagement of the OX-40 receptor in vivo enhances antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

CD91: a receptor for heat shock protein gp96

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700540

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700540

1 reference

6 August 2017

1 reference